Common brand names

• Cerubidine

How it is administered

Daunorubicin is administered as part of a fixed combination with cytarabine, encapsulated in liposomes for intravenous (IV) infusion. The medication is supplied as a sterile, preservative-free, purple, lyophilized cake in a single-dose vial. Each vial contains daunorubicin and cytarabine in a 1:5 molar ratio.

The recommended administration involves reconstituting the vial, diluting the solution, and then infusing it over 90 minutes through a central venous catheter or a peripherally inserted central catheter. The dosing schedule varies depending on the phase of treatment (induction or consolidation).

How it works

Daunorubicin is an anthracycline topoisomerase inhibitor. In the liposomal combination, it works synergistically with cytarabine to kill leukemia cells. Daunorubicin exerts its effects by forming complexes with DNA, inhibiting the enzyme topoisomerase II, and interfering with DNA polymerase activity. This disrupts DNA replication and gene expression, ultimately leading to cell death. It also produces DNA-damaging free radicals.

When encapsulated in liposomes, daunorubicin and cytarabine are delivered directly to the bone marrow, where they are taken up by leukemia cells. After cellular uptake, the liposomes degrade and release the drugs inside the cells, enhancing their effectiveness against leukemia.

Who should take it

Daunorubicin, in combination with cytarabine (as a liposomal formulation), is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older. This combination is specifically designed for patients with these subtypes of AML, which often have a poorer prognosis and may be more resistant to standard treatments.

For patients with blood cancers such as AML, this medication can be a key part of induction and consolidation therapy, aiming to achieve remission and prevent relapse.

Who should not take it

Daunorubicin should not be used in patients with a history of serious hypersensitivity reactions to daunorubicin, cytarabine, or any component of the formulation. Severe allergic reactions can be life-threatening and require immediate discontinuation of the drug.

It is also not recommended for patients with significantly impaired cardiac function, as daunorubicin carries a risk of cardiotoxicity. Patients who have reached their lifetime cumulative anthracycline exposure limit should not receive additional daunorubicin due to increased risk of heart failure. Use in pregnancy is not recommended due to the risk of harm to the fetus.

Commonly used with

Daunorubicin is most commonly used in combination with cytarabine, particularly in the liposomal formulation for the treatment of certain types of acute myeloid leukemia. This combination is designed to maximize the effectiveness of both drugs in killing leukemia cells.

Commonly tested with

Daunorubicin is often tested with cytarabine in clinical studies, especially for the treatment of AML. It may also be studied alongside other supportive care medications, such as anti-emetics, antibiotics, and drugs to manage side effects like low blood counts.